Keywords: Johnson & Johnson, Janssen-Cilag, Invega, Schizoaffective disorder, EU, Antipsychotic

Johnson & Johnson’s Invega first antipsychotic for schizoaffective disorder approved in EU

Article | 05 January 2011

Belgium-based Janssen-Cilag International, part of US health care giant Johnson & Johnson (NYSE: JNJ), yesterday received approval from the European ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Janssen-Cilag

Johnson & Johnson

Go to company listing

Related Drugs

Invega

Go to drug listing